Research Interests
Currently funded studies include the following interests:
1-Spontaneous humoral anti-tumor immunity, including the formation of Tertiary Lymphoid Structures
2-Novel antibody-based immunotherapies
3-Crosstalk between butyrophilins and gamma/delta T cells in human cancer
4-Dark matter, unconventional cancer antigens
5-Empowering CAR T cells to become effective in epithelial tumors
6-T cell lymphoma
1-Spontaneous humoral anti-tumor immunity, including the formation of Tertiary Lymphoid Structures
2-Novel antibody-based immunotherapies
3-Crosstalk between butyrophilins and gamma/delta T cells in human cancer
4-Dark matter, unconventional cancer antigens
5-Empowering CAR T cells to become effective in epithelial tumors
6-T cell lymphoma
Selected Grants
Novel immunotherapies using optimized tumor cell-penetrating antibodies
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2025 - 2029Crosstalk between butyrophilins and gamma delta T cells in human cancer
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2029Deciphering the interdependent anti-tumor potential of T and B cells within tertiary lymphoid structures
ResearchPrincipal Investigator · Awarded by Department of Defense · 2025 - 2029Inter-metastatic divergency in small cell lung cancer; implications for the design of future immunotherapies
ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2023 - 2028Process Development Grant for Gamm-delta T-cells
ResearchCollaborator · Awarded by AABB Foundation · 2025 - 2026Time restricted eating to improve immunotherapy outcomes in African American patients with Head and Neck cancer.
ResearchMentor · Awarded by Bristol-Myers Squibb Foundation · 2024 - 2026Evaluation of time restricted eating in improving immunotherapy response.
ResearchCollaborator · Awarded by Biocodex Microbiota Foundation · 2024 - 2025OR2H1 is an effective target for CAR T cells in human epithelial tumors
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2025Basic Immunology Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2020 - 2025Olfactory receptor OR2H1 as an effective target for CAR T cells in human epithelial tumors
ResearchPrincipal Investigator · Awarded by Cancer Research Institute · 2023 - 2024Targetable epigenetic mechanism driving Cutaneous T cell Lymphoma
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2024B cell-dependent anti-tumor immunity in ovarian cancer
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2024External Relationships
- Alloy Therapeutics
- Anixa Biosciences
- Canaveral
- Cellepus Therapeutics
- Compass Therapeutics
- Mays Cancer Center at UT San Antonio
- National Cancer Institute
- Ovarian Cancer Research Alliance (Scientific Advisory Board)
- University of Louisville COBRE
- University of Pittsburgh Spore in ovarian cancer
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.